These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 11912023)

  • 41. The precursor of secreted aspartic proteinase Sapp1p from Candida parapsilosis can be activated both autocatalytically and by a membrane-bound processing proteinase.
    Dostál J; Dlouhá H; Malon P; Pichová I; Hrusková-Heidingsfeldová O
    Biol Chem; 2005 Aug; 386(8):791-9. PubMed ID: 16201875
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The secretion of aspartyl proteinase, a virulence enzyme, by isolates of Candida albicans from the oral cavity of HIV-infected subjects.
    De Bernardis F; Boccanera M; Rainaldi L; Guerra CE; Quinti I; Cassone A
    Eur J Epidemiol; 1992 May; 8(3):362-7. PubMed ID: 1356827
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dynamic changes of Th1/Th2/Th17 cytokines and human beta defensin 2 in HIV-infected patients with oral candidiasis during the first year of highly active anti-retroviral therapy.
    Yong X; Liu Z; Jiang L; Tao R; Liu W; Zhang L; Peng Y; Lin X; Huang Y
    Arch Oral Biol; 2018 Aug; 92():62-67. PubMed ID: 29753928
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HIV-Protease inhibitors reduce cell adherence of Candida albicans strains by inhibition of yeast secreted aspartic proteases.
    Borg-von Zepelin M; Meyer I; Thomssen R; Würzner R; Sanglard D; Telenti A; Monod M
    J Invest Dermatol; 1999 Nov; 113(5):747-51. PubMed ID: 10571729
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Aspartic protease inhibitors: effective drugs against the human fungal pathogen Candida albicans.
    Santos AL; Braga-Silva LA
    Mini Rev Med Chem; 2013 Jan; 13(1):155-62. PubMed ID: 23256485
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Oropharyngeal yeast colonization in HIV-infected outpatients in southern Taiwan: CD4 count, efavirenz therapy and intravenous drug use matter.
    Wu CJ; Lee HC; Yang YL; Chang CM; Chen HT; Lin CC; Lee NY; Chu WL; Hsieh LY; Wang YL; Lauderale TL; Tseng FC; Ko NY; Ko WC; Lo HJ
    Clin Microbiol Infect; 2012 May; 18(5):485-90. PubMed ID: 21939471
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Secreted aspartic proteases of Candida albicans, Candida tropicalis, Candida parapsilosis and Candida lusitaniae. Inhibition with peptidomimetic inhibitors.
    Pichová I; Pavlícková L; Dostál J; Dolejsí E; Hrusková-Heidingsfeldová O; Weber J; Ruml T; Soucek M
    Eur J Biochem; 2001 May; 268(9):2669-77. PubMed ID: 11322888
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Factors related to oral candidiasis in HIV children and adolescents, species characterization and antifungal susceptibility].
    Castillo-Martínez NA; Mouriño-Pérez RR; Cornejo-Bravo JM; Gaitán-Cepeda LA
    Rev Chilena Infectol; 2018 Aug; 35(4):377-385. PubMed ID: 30534924
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Viral proteinases--possible targets of antiviral drugs.
    Maliar T; Baláz S; Tandlich R; Sturdík E
    Acta Virol; 2002; 46(3):131-40. PubMed ID: 12580374
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of PI-HAART on the prevalence of oral lesions in HIV-1 infected patients. A Greek study.
    Nicolatou-Galitis O; Velegraki A; Paikos S; Economopoulou P; Stefaniotis T; Papanikolaou IS; Kordossis T
    Oral Dis; 2004 May; 10(3):145-50. PubMed ID: 15089923
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV infection: a prospective case-control study.
    Cauda R; Tacconelli E; Tumbarello M; Morace G; De Bernardis F; Torosantucci A; Cassone A
    J Acquir Immune Defic Syndr; 1999 May; 21(1):20-5. PubMed ID: 10235510
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Structure of secreted aspartic proteinases from Candida. Implications for the design of antifungal agents.
    Abad-Zapatero C; Goldman R; Muchmore SW; Hutchins C; Oie T; Stewart K; Cutfield SM; Cutfield JF; Foundling SI; Ray TL
    Adv Exp Med Biol; 1998; 436():297-313. PubMed ID: 9561233
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vivo expression and localization of Candida albicans secreted aspartyl proteinases during oral candidiasis in HIV-infected patients.
    Schaller M; Hube B; Ollert MW; Schäfer W; Borg-von Zepelin M; Thoma-Greber E; Korting HC
    J Invest Dermatol; 1999 Mar; 112(3):383-6. PubMed ID: 10084319
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Multiplicity of genes encoding secreted aspartic proteinases in Candida species.
    Monod M; Togni G; Hube B; Sanglard D
    Mol Microbiol; 1994 Jul; 13(2):357-68. PubMed ID: 7984113
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Characterization of Candida parapsilosis infection of an in vitro reconstituted human oral epithelium.
    Silva S; Henriques M; Oliveira R; Azeredo J; Malic S; Hooper SJ; Williams DW
    Eur J Oral Sci; 2009 Dec; 117(6):669-75. PubMed ID: 20121929
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The changing role of HIV-associated oral candidiasis in the era of HAART.
    Patuwo C; Young K; Lin M; Pardi V; Murata RM
    J Calif Dent Assoc; 2015 Feb; 43(2):87-92. PubMed ID: 25868223
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reduction in oropharyngeal candidiasis following introduction of protease inhibitors.
    Hood S; Bonington A; Evans J; Denning D
    AIDS; 1998 Mar; 12(4):447-8. PubMed ID: 9520182
    [No Abstract]   [Full Text] [Related]  

  • 58. Candida species from oral cavity of HIV-infected children exhibit reduced virulence factors in the HAART era.
    Portela MB; Lima de Amorim E; Santos AM; Alexandre da Rocha Curvelo J; de Oliveira Martins K; Capillé CL; Maria de Araújo Soares R; Barbosa de Araújo Castro GF
    Microb Pathog; 2017 Jan; 102():74-81. PubMed ID: 27913142
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Oral lesions in HIV/AIDS patients undergoing highly active antiretroviral treatment including protease inhibitors: a new face of oral AIDS?
    Ceballos-Salobreña A; Gaitán-Cepeda LA; Ceballos-Garcia L; Lezama-Del Valle D
    AIDS Patient Care STDS; 2000 Dec; 14(12):627-35. PubMed ID: 11119429
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oral Candida flora from Brazilian human immunodeficiency virus-infected patients in the highly active antiretroviral therapy era.
    Melo NR; Taguchi H; Jorge J; Pedro RJ; Almeida OP; Fukushima K; Nishimura K; Miyaji M
    Mem Inst Oswaldo Cruz; 2004 Jun; 99(4):425-31. PubMed ID: 15322634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.